Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use

Hehme, Norbert; Engelmann, H.; Kuenzel, Wayne J.; Neumeier, Elisabeth; Saenger, Roland

doi:10.1016/j.virusres.2004.02.029

Cited by 103 publications

(53 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some adjuvants, such as MF59 [27] [28], aluminum compounds (Alum) [29], and QS-21 [30], have been proposed to improve the immunogenicity of H5N1 vaccines. A major limitation in the use of alum for a variety of vaccines is that it fails to induce Th1 immune responses and stimulates cell-mediated immune responses [31].…”

mentioning

confidence: 99%

Platycodin D Improves the Immunogenicity of Newcastle Disease Virus‐Based Recombinant Avian Influenza Vaccine in Mice

Xie

Sun

2010

Chemistry & Biodiversity

View full text Add to dashboard Cite

The development of an effective influenza vaccine is urgently important for controlling outbreaks of the highly pathogenic avian influenza virus (HPAIV) and reducing the impact of pandemics. The use of an adjuvant in such a vaccine can significantly contribute to improve the immunogenicity. To explore a novel and safe adjuvant for improving the potency of influenza vaccines, platycodin D (1), a saponin from the root of Platycodon grandiflorum, was evaluated for the adjuvant potentials on the specific cellular and humoral immune responses to Newcastle disease virus-based recombinant avian influenza vaccine (rL-H5) in mice. Compound 1 significantly promoted the concanavalin A (Con A)-, the lipopolysaccharide (LPS)-, and the antigen-induced splenocyte proliferation and enhanced the serum antigen-specific IgG, IgG1, IgG2a, and IgG2b antibody titers (P<0.05, P<0.01, or P<0.001) in mice immunized with rL-H5. The mRNA expressions of Th1/Th2 cytokines (IFN-gamma and IL-10) and transcription factors (T-bet and GATA-3) in splenocytes were also markedly up-regulated by 1, compared with the control group immunized with rL-H5 alone (P<0.01 or P<0.001). In addition, 1 remarkably increased the killing activities of natural killer (NK) cells from splenocytes in the immunized mice (P<0.05), which may have important implications for the vaccination against the avian influenza virus. We concluded that 1 could improve the immunogenicity of the rL-H5 vaccine by enhancing both humoral and cellular immune responses in mice, and that 1 is a promising adjuvant for influenza vaccines.

show abstract

mentioning

confidence: 99%

Platycodin D Improves the Immunogenicity of Newcastle Disease Virus‐Based Recombinant Avian Influenza Vaccine in Mice

Xie

Sun

2010

Chemistry & Biodiversity

View full text Add to dashboard Cite

show abstract

“…Overall, whole virus vaccines appear to perform better than subvirion vaccines when formulated with aluminium adjuvants. In a study using two doses of a putative pandemic vaccine containing H2N2 whole virus adjuvanted with alum it was shown that as little as 1.9 μg HA gave a seroprotection rate of 82% in immunologically naïve subjects, compared to 98% for a standard split and non‐adjuvanted 15 μg HA vaccine 21 . Similar results were obtained for an H9N2 vaccine 22 .…”

Section: Pandemic Vaccinesmentioning

confidence: 62%

Vaccines for an influenza pandemic: scientific and political challenges

Haaheim

2007

Influenza Resp Viruses

View full text Add to dashboard Cite

So far, most published results from clinical trials using various avian influenza virus vaccine formulations have been disappointing. Should the pandemic strike, we still do not have the ability to provide an efficacious pandemic vaccine in time and in sufficient quantities for the world. The H5N1 enzootic could potentially give rise to a pandemic at any time. Transcontinental air traffic could seed the pandemic virus to most corners of the globe within a few weeks/months. We still have a unique window of opportunity to stimulate and support academia and the pharmaceutical industry to accelerate the urgently needed vaccine research. The political inertia is surprising, particularly as politicians, if and when a pandemic eventuates, will be asked why, despite repeated warnings, they did not take appropriate action in time. It is a governmental obligation – and not that of the WHO or the pharmaceutical industry – to protect their nationals. Moreover, when the poorer nations of this world realize that equitable quantities of the scarce supplies of vaccines, drugs and medical essentials will not come their way, the post‐pandemic international scene will be one of even more deep distrust for many years. This scenario is not acceptable.

show abstract

“…Allerdings muss auch betont werden, dass das Konzept der Antigeneinsparung durch die Verwendung von AlOH zur Auffrischung einer vorbestehenden Grundimmunität entwickelt wurde [7,8].…”

Section: Adjuvanssystemeunclassified

Pandemische Influenzaimpfstoffe

Pfleiderer

2010

Bundesgesundheitsbl.

View full text Add to dashboard Cite

The concept of identifying appropriate scientific and regulatory principles to ensure rapid availability of pandemic influenza vaccines when needed were already developed starting in the year 2003. These principles allowed licensing of three so-called mock-up vaccines far ahead of any real presenting pandemic event. Those licenses (Marketing Authorizations) were immediately adapted to the novel H1N1 strain shortly after its identification in April 2009 ensuring that as early as September 2009 large parts of the German as well as of the EU population had access to licensed products which had undergone sufficient evaluation before first use in humans. In contrast, for pandemic vaccine concepts without a previously licensed mock-up version it generally took twice as much time to accumulate data supporting the granting of a Marketing Authorization. This article describes in detail the translation of concepts of producing, testing, and licensing of pandemic influenza vaccines into practice under real conditions.

show abstract

Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use

Cited by 103 publications

References 15 publications

Platycodin D Improves the Immunogenicity of Newcastle Disease Virus‐Based Recombinant Avian Influenza Vaccine in Mice

Platycodin D Improves the Immunogenicity of Newcastle Disease Virus‐Based Recombinant Avian Influenza Vaccine in Mice

Vaccines for an influenza pandemic: scientific and political challenges

Pandemische Influenzaimpfstoffe

Contact Info

Product

Resources

About